Baolan Li
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 33
- Lung Cancer Diagnosis and Treatment 4
- Medical Imaging and Pathology Studies 3
- Oncology 23
- Cancer Immunotherapy and Biomarkers 11
- Lung Cancer Research Studies 9
- Cancer Cells and Metastasis 2
- Co-authors
- Ying Hu (6 shared papers)Mingming Hu (6 shared papers)Jiabei He (2 shared papers)Tongmei Zhang (22 shared papers)Yi Luo (3 shared papers)Baohui Han (3 shared papers)Kai Li (3 shared papers)Zhehai Wang (3 shared papers)
- Journals
- Journal of Thoracic Oncology (6 papers)BMC Cancer (3 papers)The Lancet Respiratory Medicine (3 papers)Translational Lung Cancer Research (3 papers)The Lancet Oncology (2 papers)
- Partner nations
- ChinaGermanyUnited States
In The Last Decade
Baolan Li
62 papers receiving 3.1k citations
Baolan Li's Hit Papers
Peers
Comparison fields: 5 of 73
- Oncology 1.4k
- Pulmonary and Respiratory Medicine 1.4k
- Cancer Research 151
- Otorhinolaryngology 33
- Immunology 91
Countries citing papers authored by Baolan Li
This map shows the geographic impact of Baolan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baolan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baolan Li more than expected).
Fields of papers citing papers by Baolan Li
This network shows the impact of papers produced by Baolan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baolan Li. The network helps show where Baolan Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Baolan Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer Hit paper breakdown → | 2018 | 503 |
| 2 | 2015 | 346 | |
| 3 | 2020 | 305 | |
| 4 | Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) Hit paper breakdown → | 2021 | 249 |
| 5 | 2018 | 210 | |
| 6 | AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations Hit paper breakdown → | 2022 | 210 |
| 7 | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial Hit paper breakdown → | 2022 | 178 |
| 8 | Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 152 |
| 9 | 2022 | 138 | |
| 10 | 2021 | 113 | |
| 11 | Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial Hit paper breakdown → | 2024 | 89 |
| 12 | 2019 | 48 | |
| 13 | 2015 | 45 | |
| 14 | 2015 | 40 | |
| 15 | 2019 | 36 | |
| 16 | 2018 | 33 | |
| 17 | 2019 | 33 | |
| 18 | 2014 | 31 | |
| 19 | 2015 | 30 | |
| 20 | 2021 | 29 |
About Baolan Li
Baolan Li is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Immunology and Surgery, having authored 62 papers that have together received 3.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (33 papers), Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Research Studies (9 papers), Cancer Genomics and Diagnostics (5 papers), Lung Cancer Diagnosis and Treatment (4 papers), Medical Imaging and Pathology Studies (3 papers), Congenital Diaphragmatic Hernia Studies (3 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Oncology (1.4k citations), Pulmonary and Respiratory Medicine (1.4k citations), Cancer Research (151 citations), Otorhinolaryngology (33 citations) and Immunology (91 citations). Baolan Li has collaborated with scholars based in China, Germany and United States. Frequent co-authors include Ying Hu, Mingming Hu, Jiabei He, Tongmei Zhang, Yi Luo, Baohui Han, Kai Li, Zhehai Wang, Yuankai Shi and Yizhuo Zhao. Their work appears in journals such as Journal of Thoracic Oncology, BMC Cancer, The Lancet Respiratory Medicine, Translational Lung Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.